Brief: Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis
23/05/2025 13:46
May 23 (Reuters) - Crescita Therapeutics Inc CTX.TO: CRESCITA THERAPEUTICS ANNOUNCES MUTUAL TERMINATION OF LICENSING AGREEMENT WITH CROMA PHARMA GMBH FOR PLIAGLIS® CRESCITA THERAPEUTICS INC - TO EXPLORE NEW PARTNERSHIPS FOR PLIAGLIS COMMERCIALIZATION Source text: ID:nBwyKfGLa Further company coverage: CTX.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescita Therapeutics
See all newsBrief: Crescita Therapeutics Obtains Shareholder Approval To Be Acquired By Clinactiv Holdings
Canada's Crescita Q1 revenue rises on manufacturing growth
Canada's Crescita Q4 revenue falls on prior-year one-time reimbursement
Brief: Crescita Reports Q4 And Fiscal 2025 Results
Brief: Crescita Announces Definitive Agreement To Be Acquired By Clinactiv Holdings In An All-Cash Transaction At A Significant Premium